Table 2.

Univariable and multivariable competing-risks regression models for urethral cancer patients (Urothelial vs. Variant histology/Urothelial vs. SCC).

	CSM Urothelial vs. Variant histology				CSM Urothelial vs. SCC
	Univariable		Multivariable		Univariable		Multivariable
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Histology
Urothelial	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
Variant histology/SCC	1.53 (1.23–1.91)	<0.001	1.35 (1.07–1.69)	0.01	1.35 (1.02–1.80)	0.036	1.17 (0.87–1.59)	0.3
Race/ethnicity
Caucasian	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
African American	1.80 (1.39–2.32)	<0.001	1.64 (1.26–2.12)	<0.001	1.60 (1.12–2.28)	<0.01	1.44 (1.01–2.07)	0.045
Hispanic	1.31 (0.85–2.00)	0.2	1.28 (0.83–1.97)	0.3	1.26 (0.72–2.21)	0.4	1.4 (0.8–2.44)	0.2
Other	1.58 (1.04–2.40)	0.03	1.45 (0.95–2.21)	0.09	1.54 (0.82–2.87)	0.18	1.33 (0.71–2.51)	0.4
Treatment
Endoscopic/Surgery	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---	1.00 (Ref.)	---
Bi-/Trimodality	1.65 (1.27–2.15)	<0.001	1.67 (1.28–2.18)	<0.001	2.44 (1.71–3.49)	<0.001	2.47 (1.72–3.55)	<0.001
Systemic chemotherapy	3.01 (2.18–4.16)	<0.001	2.89 (2.09–3.99)	<0.001	4.24 (2.77–6.49)	<0.001	4.06 (2.61–6.29)	<0.001
Unknown	2.70 (1.96–3.71)	<0.001	2.62 (1.9–3.61)	<0.001	3.54 (2.28–5.51)	<0.001	3.38 (2.17–5.26)	<0.001

Univariable and multivariable competing-risks regression models for urethral cancer patients matched for TNM-stage and age for urothelial vs. variant histology and subsequently for urothelial vs. squamous cell carcinoma.

CSM, Cancer specific mortality; SCC, Squamous cell carcinoma; HR, Hazard ratio; CI, Confidence interval.